share_log

Sonendo Strengthens Leadership With Key Strategic Appointments

Sonendo Strengthens Leadership With Key Strategic Appointments

Sonendo通過重要的戰略任命來加強領導力
Sonendo ·  06/05 00:00

John Bostjancic Appointed as Chief Financial Officer
Bob Guyatt Appointed as Senior Vice President of Marketing
John McGaugh Promoted to Senior Vice President of Operations

John Bostjancic被任命爲致富金融的首席財務官。
Bob Guyatt被任命爲市場營銷高級副總裁。
John McGaugh晉升爲高級副總裁。

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Sonendo, Inc. (OTCQX: SONX) ("Sonendo"), a leading dental technology company and developer of the GentleWave System, today announced the appointment of John Bostjancic as Chief Financial Officer, the appointment of Robert Guyatt as Senior Vice President of Marketing, and the promotion of John McGaugh to Senior Vice President of Operations.

加利福尼亞州拉古納希爾斯--(BUSINESS WIRE)--Sonendo, Inc. (OTCQX: SONX) ("Sonendo"),一家領先的牙科技術公司和GentleWave系統的開發商,今天宣佈任命John Bostjancic爲首席財務官,任命Robert Guyatt爲市場營銷高級副總裁,晉升John McGaugh爲高級副總裁。

"Sonendo is embarking on a reset strategy to drive fundamental change within the organization," said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "We have filled key leadership roles with action-minded individuals who are committed to help drive the three elements of our reset: commercial execution, margin expansion, and cash conservation. I'm thrilled to have John Bostjancic, Bob Guyatt, and John McGaugh onboard, and believe their contributions to Sonendo will be key factors in the success of each facet of our forward-looking strategy."

"Sonendo正在啓動重置策略,以推動組織內的根本性變化, "說Sonendo的總裁兼首席執行官Bjarne Bergheim。"我們已經填補了關鍵領導職位,領導者是行動堅定的人,致力於幫助推動我們重置的三個要素:商業執行,邊際擴張和現金保護。我很高興John Bostjancic,Bob Guyatt和John McGaugh能加入,並相信他們對Sonendo的貢獻將是實現我們前瞻性策略成功的關鍵因素。"

Mr. Bostjancic comes to Sonendo with extensive experience in the medical device industry with over 20 years in financial and operational leadership roles at publicly traded companies. He most recently served as Chief Financial Officer of Orthofix Medical, a global spinal and orthopedics medical device company, following its 2023 merger with SeaSpine, where Bostjancic had served for 8 years as CFO and was also appointed as Chief Operating Officer in 2022. Prior to that, he spent 16 years at Integra Lifesciences in multiple corporate development, supply chain and financial leadership roles. Bostjancic began his career at PricewaterhouseCoopers LLP before joining the accounting standards team at Merck & Co Inc. His appointment as Chief Financial Officer at Sonendo is effective as of June 5, 2024.

Bostjancic先生具有超過20年醫療器械行業財務和運營領導崗位的廣泛經驗,曾在多家上市公司擔任這些職務。最近,他擔任全球脊柱和骨科醫療器械公司Orthofix Medical的首席財務官,隨着2023年與SeaSpine的合併。在SeaSpine任CFO八年的時間裏,並在2022年被任命爲COO。在此之前,他在Integra Lifesciences擔任多個企業發展、供應鏈和財務領導職務長達16年。Bostjancic先生在加入Sonendo之前曾在PricewaterhouseCoopers LLP開始了他的職業生涯,後來加入了默沙東公司會計準則團隊。他被任命爲Sonendo的首席財務官,任期自2024年6月5日開始。

Mr. Bergheim added, "I'm very pleased to welcome John to the Sonendo team and know that with his strong track record of championing growth initiatives while enhancing efficiencies, he will be instrumental in executing across all aspects of the Company's reset strategy. John is a veteran of the healthcare industry, and we look forward to leveraging his deep expertise as we move on to the next step in Sonendo's journey."

Bergheim先生表示:"我非常高興歡迎John加入Sonendo團隊,相信憑藉他在推進增長和提高效率方面的卓越記錄,他將在執行公司的重置策略的各個方面發揮重要作用。John是醫療保健行業的一位老將,我們期待利用他的深厚專業知識,邁向Sonendo旅程的下一步。"

Mr. Guyatt brings comprehensive marketing leadership and experience to Sonendo, where he will head marketing efforts, which include driving the commercial execution initiative associated with the Company's reset strategy. He previously served as a consultant to the Company in other senior marketing positions. Prior to his time at Sonendo, Mr. Guyatt held global executive marketing roles at Danaher's dental platform and led US Sales and Global Marketing at Lifecore Biomedical before an acquisition by Warburg Pincus. His appointment as Senior Vice President of Marketing at Sonendo was effective as of April 23, 2024.

Guyatt先生爲Sonendo帶來全面的營銷領導力和經驗,他將領導包括推動與公司重置策略相關的商業執行倡議在內的營銷工作。他曾在該公司擔任其他高級營銷職位的顧問。在加入Sonendo之前,Guyatt先生曾在丹納赫公司的牙科平台擔任全球執行營銷職務,並在被Warburg Pincus收購之前領導Lifecore Biomedical的美國銷售和全球營銷。他的任命日期是2024年4月23日,擔任Sonendo的市場營銷高級副總裁。

Mr. McGaugh has been with Sonendo since May 2023 where he has helped instill significant operational efficiencies with console assembly and procedure instrument margin contributions. He has a proven record with over 20 years in overseeing global manufacturing operations, and with his promotion he will take on an expanded leadership role within the organization. Prior to his time at Sonendo, Mr. McGaugh served as a multi-site operational leader for Abbott Vascular. In addition to his experience at Abbott, Mr. McGaugh has held leadership roles at Boston Scientific and American Medical Systems. His promotion to Senior Vice President of Operations was effective as of March 1, 2024.

自2023年5月以來,McGaugh先生一直在Sonendo工作,他幫助實現了對控制檯組裝和程序工具邊際貢獻的顯着運營效率提升。他在監督全球製造業務流程方面擁有20多年的經驗,在晉升後,他將在組織內擔任擴展領導職責。在加入Sonendo之前,McGaugh先生曾爲Abbott Vascular擔任多個現場運營領導職位。除了在Abbott的經驗之外,McGaugh先生還曾在Boston Scientific和美國醫療系統擔任領導職位。他的晉升日期是2024年3月1日,擔任Sonendo的高級副總裁。

About Sonendo

關於Sonendo

Sonendo is a commercial-stage medical technology company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy, and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices and offers patients an effective, less invasive, and less painful alternative to traditional root canal therapy.

Sonendo是一家商業化階段的醫療技術公司,致力於拯救牙齒脫離牙齒蛀壞,這是全球最常見的慢性疾病。Sonendo開發和製造了GentleWave系統,這是一種創新的技術平台,專門設計用於清潔和消毒牙齒內微小的空間,而無需去除牙齒結構。該系統利用一種專有作用機制,結合程序流體優化、廣譜聲能和先進流體動力學,對複雜的根管系統深部區域進行去污和消毒,實施方法更少侵入性、能保護牙齒結構。與傳統的根管治療方法相比,GentleWave系統的臨床效益包括改善臨床結果,無論根管複雜性和牙齒解剖形態如何,都能達到卓越的清潔效果,出血和創傷更少,恢復和治療速度更快,術後痛苦減輕甚至完全沒有。此外,GentleWave系統可以提高牙科實踐的工作流程和經濟效益,爲患者提供有效的,侵入性更少和疼痛更輕的傳統根管治療替代方案。

For more information about Sonendo and the GentleWave System, please visit www.sonendo.com. To find a GentleWave doctor in your area, please visit www.gentlewave.com.

欲了解更多關於Sonendo和GentleWave System的信息,請訪問www.sonendo.com要查找您所在地區的GentleWave醫生,請訪問www.gentlewave.com.

Forward-Looking Statements

前瞻性聲明

This press release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, express or implied forward-looking statements relating to the Company's anticipated business and financial performance on an on-going basis. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in our registration statements, reports and other filings with the Securities and Exchange Commission, including the "Risk Factors" set forth in our Annual Report on Form 10-K, as supplemented by our quarterly reports on Form 10-Q. Such filings are available on our website or at www.sec.gov. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

本新聞稿包括前瞻性聲明(非歷史事實的聲明),根據1995年《私人證券訴訟改革法》。這些聲明包括但不限於關於公司預計的業務和財務績效的明示或暗示前瞻性聲明。請注意,這些聲明並非未來績效的保證,而我們的實際結果可能與前瞻性聲明所述的結果有所不同。前瞻性聲明是基於當前的預期和假設對未來事件進行預測、預估和其他聲明的;僅適用於它們發表的日期;因此,它們隨時可能受到發生變化的風險和不確定性的影響。導致公司實際結果與這些前瞻性聲明有實質性不同的因素,詳見我們在註冊聲明、報告和其他提交證券交易委員會的文件,包括我們的《10-k表》中列出的"風險因素",以及我們的季報表格10-Q,這些文件可在我們的網站或上面找到。www.sec.govwww.sec.gov

Investor Contact:

投資者聯繫人:

Gilmartin Group
Greg Chodaczek
IR@Sonendo.com

吉爾馬丁集團
Greg Chodaczek
IR@Sonendo.com

Source: Sonendo

來源:Sonendo

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論